1. Home
  2. ENSC vs GSIW Comparison

ENSC vs GSIW Comparison

Compare ENSC & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • GSIW
  • Stock Information
  • Founded
  • ENSC 2003
  • GSIW 2016
  • Country
  • ENSC United States
  • GSIW Hong Kong
  • Employees
  • ENSC N/A
  • GSIW N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • GSIW
  • Sector
  • ENSC Health Care
  • GSIW
  • Exchange
  • ENSC Nasdaq
  • GSIW Nasdaq
  • Market Cap
  • ENSC 9.5M
  • GSIW 10.5M
  • IPO Year
  • ENSC N/A
  • GSIW 2023
  • Fundamental
  • Price
  • ENSC $6.07
  • GSIW $0.57
  • Analyst Decision
  • ENSC
  • GSIW
  • Analyst Count
  • ENSC 0
  • GSIW 0
  • Target Price
  • ENSC N/A
  • GSIW N/A
  • AVG Volume (30 Days)
  • ENSC 154.9K
  • GSIW 156.5K
  • Earning Date
  • ENSC 11-12-2024
  • GSIW 12-31-2024
  • Dividend Yield
  • ENSC N/A
  • GSIW N/A
  • EPS Growth
  • ENSC N/A
  • GSIW N/A
  • EPS
  • ENSC N/A
  • GSIW N/A
  • Revenue
  • ENSC $4,421,404.00
  • GSIW $1,408,469.00
  • Revenue This Year
  • ENSC N/A
  • GSIW N/A
  • Revenue Next Year
  • ENSC N/A
  • GSIW N/A
  • P/E Ratio
  • ENSC N/A
  • GSIW N/A
  • Revenue Growth
  • ENSC 40.41
  • GSIW N/A
  • 52 Week Low
  • ENSC $2.12
  • GSIW $0.53
  • 52 Week High
  • ENSC $30.90
  • GSIW $15.99
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 42.77
  • GSIW 36.17
  • Support Level
  • ENSC $5.34
  • GSIW $0.55
  • Resistance Level
  • ENSC $8.27
  • GSIW $0.64
  • Average True Range (ATR)
  • ENSC 1.06
  • GSIW 0.06
  • MACD
  • ENSC -0.24
  • GSIW 0.04
  • Stochastic Oscillator
  • ENSC 18.43
  • GSIW 16.67

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: